First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

Overview

This study will evaluate the safety, tolerability, and pharmacokinetics of BGB-23339 and food effects in healthy participants

Full Title of Study: “A First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 15, 2022

Interventions

  • Drug: BGB-23339
    • Administered orally as a tablet
  • Drug: Placebo
    • Administered orally as a tablet

Arms, Groups and Cohorts

  • Experimental: Part A Dose Escalation (Single Ascending Dose)
    • Up to 5 dose levels of BGB-23339 or Placebo
  • Experimental: Part B Dose Escalation (Multiple Ascending Dose)
    • Up to 4 dose levels of BGB-23339 or placebo based on data collected in Part A
  • Experimental: Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)
    • Up to 2 dose levels of BGB-23339 or placebo based on data collected in Part A and B (conducted in China only)
  • Experimental: Part D (Food-Effect Study)
    • Three single dose levels of BGB-23339 under different feeding conditions

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Experiencing Adverse Events (AEs)
    • Time Frame: Up to approximately 7 weeks
  • Number of participants with clinically significant changes from baseline in vital signs
    • Time Frame: Up to approximately 4 weeks
    • Vital signs include blood pressure and pulse rate
  • Number of participants with clinically significant changes from baseline in clinical laboratory values
    • Time Frame: Up to approximately 4 weeks
    • Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis

Secondary Measures

  • Area under the plasma concentration-time curve from time zero to last quantifiable time (AUClast) for Parts A, B, C and D
    • Time Frame: Up to approximately 4 weeks
  • Area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC0-24) for Part D only
    • Time Frame: Up to approximately 4 weeks
  • Area under the plasma concentration-time curve from time zero to end of dosing interval (AUCtau) for Parts A, B, C and D
    • Time Frame: Up to approximately 4 weeks
  • Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for Parts A, B, C, and D
    • Time Frame: Up to approximately 4 weeks
  • Maximum observed plasma concentration (Cmax) for Parts A, B, C and D
    • Time Frame: Up to approximately 4 weeks
  • Time to maximum plasma concentration (Tmax) for Parts A, B, C and D
    • Time Frame: Up to approximately 4 weeks
  • Trough plasma concentration (Ctrough) for Parts A, B, and C
    • Time Frame: Up to approximately 4 weeks
  • Apparent terminal elimination half-life (t½) for Parts A, B, C and D
    • Time Frame: Up to approximately 4 weeks
    • in fed and fasted states for BGB-23339
  • Apparent systemic clearance (CL/F) for Parts A, B, and C
    • Time Frame: Up to approximately 4 weeks
  • Apparent volume of distribution (Vz/F) for Parts A, B, and C
    • Time Frame: Up to approximately 4 weeks
  • Accumulation ratios, and metabolite to parent ratio for BGB-23339 and its metabolite BGB-25808 as appropriate for Parts A, B, C and D
    • Time Frame: Up to approximately 4 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Signed informed consent form (ICF) and able to comply with study requirements 2. Healthy men and/or women of no childbearing potential of age ≥ 18 years and ≤ 55 years on the day of signing the ICF (or the legal age of consent) for Parts A, B and D; of age≥ 18 years and ≤ 45 years on the day of signing the ICF (or the legal age of consent) and of Chinese descent for Part C 3. Participants are in good general health as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring 4. Body weight ≥ 50 kg and body mass index (BMI) within the range 18 to 32 kg/m2 (inclusive) 5. A nonsterile man with a female partner of childbearing potential must be willing to use a highly effective method of birth control from the time of study enrollment until 90 days after the last dose of study drug 6. A woman of no childbearing potential must meet at least one of the following criteria: 1. Postmenopausal status, defined as: cessation of regular menses for ≥ 12 consecutive months (menopause confirmed by Follicular Stimulating Hormone [FSH] levels and Luteinizing Hormone [LH] levels as defined by the established reference ranges) 2. Surgically sterile (eg, hysterectomy, oophorectomy, or tubal ligation for at least the past 3 months). Exclusion Criteria:

1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data 2. Abnormal blood pressure as determined by the investigator 3. Active herpes infection, including herpes simplex 1 and 2 and herpes zoster (demonstrated on physical examination and/or medical history ≤ 2 months before randomization) 4. Any malignancies within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years 5. Past or intended use of prescription medication ≤ 14 days and over-the-counter (OTC) medication including herbal, vitamins and dietary supplements ≤ 7 days before randomization 6. Live vaccine ≤ 30 days, and/or vaccine of any type ≤ 14 days before randomization 7. Has received an investigational product within the following time before randomization: 3 months, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer) 8. Participation in a prior study that would result in loss of blood or blood products in excess of 500 mL within 56 days before randomization 9. Exposure to ≥ 4 new chemical entities within 12 months before randomization 10. Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or ≤ 3 months before randomization 11. Regular alcohol consumption ≤ 3 months before randomization 12. Regular use of recreational drugs 13. Current use and/or has used nicotine or nicotine-containing products (eg, nicotine patch and electronic cigarette) within 14 days before randomization Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • BeiGene
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.